Video
Would Outcomes-Based Contracting be Beneficial for Orphan Drugs?
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.
Outcomes-based contracting can be very beneficial for specialty pharmacies, and we certainly have a role to play. We are at the center of the patients care once they leave the physician’s office, particularly with the new oral and self-administered medications.
That being said, there’s only certain factors that as a pharmacy we can control related to those outcomes. So, I think where the value comes into outcomes-based contracting is really helping us as pharmacies show what we can control and how we can impact patient outcomes.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
